rPSGL-Ig. Treatment of acute myocardial infarction, thrombolytic, P-selectin inhibitor

Drugs of the Future

Volumn 27, Issue 4, 2002, Pages 346-349

  Diaz Ricart, Maribel ^a   Bozzo, J ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; RECOMBINANT P SELECTIN GLYCOPROTEIN LIGAND IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BABOON; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFORMATION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MOUSE; NONHUMAN; NORMAL HUMAN; RAT; RESTENOSIS; REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 0036278367     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.04.668529     Document Type: Review

References (27)

1. Structure and function of P-selectin glycoprotein ligand-1
2. Core2 β-1,6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin
3. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region
4. Two by two: The pairings of P-selectin and P-selectin glycoprotein ligand 1
5. Integrins and other cell adhesion molecules
6. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets
7. GMP-140, a platelet α-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies
8. Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow
9. P-selectin and PSGL-1: Exploiting connections between inflammation and venous thrombosis
10. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model
11. Neutrophil implications in platelet deposition and vasoconstriction after deep arterial injury by angioplasty in pigs
12. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate
13. Ultrastructural expression of P-selectin on surface activated platelets
14. The role of platelets in the early and late vascular responses initiated by mechanical vascular injury
15. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
16. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor
17. P-Selectin induces the expression of tissue factor on monocytes
18. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation
19. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
20. Recombinant soluble P-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine
21. P-Selectin antagonism with recombinant P-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces
22. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model
23. P- Selectin antagonism causes dose-dependent venous thrombosis inhibition
24. New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig
25. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL Ig for phase I trial
26. Safety, tolerability and pharmacokinetics of recombinant P-selectin glycoprotein ligandIg (rPSGL-Ig) in healthy young and elderly subjects
27. Wyeth to discontinue development of rPSGL-Ig for myocardial infarction